7th Sachs Annual Neuroscience Innovation Forum13rd Annual LifeSci Advisors Corporate Access EventBiotech Showcase-2024 42nd Annual J.P. Morgan Healthcare ConferenceInvest Securities...
-- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study...
WATERTOWN, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug...
- Collaboration with gene therapy leader Novartis aims to discover and develop new approaches for Huntington’s disease and spinal muscular...
VANCOUVER, British Columbia, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or...
Dr. Beena Ahmed appointed vice president of Conferences Dr. Natalie Mrachacz-Kersting appointed vice president of Member and Student Activities Two-year...
BURLINGTON, Mass. and JERUSALEM, Dec. 19, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
New accessory for NeuroStar TMS reduces patient setup steps and improves efficiency for providersMALVERN, Pa., Dec. 18, 2023 (GLOBE NEWSWIRE)...
Leading Healthcare Consultancy Meets Increasing Demand for Data-Driven InsightsLOUISVILLE, KY / ACCESSWIRE / December 15, 2023 / HSG Advisors, a...
EDEN PRAIRIE, Minn., Dec. 14, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a...
Company Appoints Mohammad Shokoohi-Yekta to Lead Program and Industry Pioneer Lance Myers as AdvisorSANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT),...
Initiative enhances Baptist Health South Florida's efforts in medical innovation for advanced research and collaborative development.PALO ALTO, CA / ACCESSWIRE...
Company to review BXCL502 and other potential emerging pipeline candidates Dr. Jeffrey Cummings to discuss agitation relief in Alzheimer’s disease and...
WATERTOWN, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug...
The option agreement grants NLS Pharmaceutics Ltd. the exclusive option to in-license all of Aexon Labs' assets for the potential...
Expanse Oncology the next step toward creating a single, patient-centered EHRCANTON, Mass.--(BUSINESS WIRE)--St. Joseph’s/Candler Health System (Savannah, GA) has taken...
-- Company on track to submit PAS-004 IND application in current quarter -- -- Pasithea plans to begin PAS-004 Phase 1 dose...
Event will focus on tavapadon, a D1/D5 partial agonist in Phase 3 development for the treatment of Parkinson’s disease Live...
NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor, a clinically validated target for the treatment...
VANCOUVER, British Columbia, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB:...